

References

I-157

1. Hache M, Swoboda KJ, Sethna N, et al. Intrathecal Injections in Children With Spinal Muscular Atrophy; Nusinersen Clinical Trial Experience. *J Child Neuro*. 2016;899-906.
2. Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. *Lancet*. 2016;3017-3026.
3. Ionis Pharmaceuticals, Inc. A Study to Assess the Efficacy and Safety of IONIS-SMN Rx in Infants with Spinal Muscular Atrophy. NLM Identifier: NCT02193074.
4. SPINRAZA™ [package insert]. Cambridge, MA: Biogen Inc. 2016.
5. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. *N Engl J Med*. 2018;378:625-35.
6. MICROMEDEX®SOLUTIONS Compendia. 2018. Nusinersen.
7. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Nusinersen.
8. Hayes, Inc. Hayes Health Technology Brief. Nusinersen (Spinraza; Biogen) for Spinal Muscular Atroph). Lansdale, PA: Hayes, Inc.; June, 2018.